BeiGene, Ltd. (6160.HK)
HKD 105.9
(-1.4%)
HKD 105.9
(-1.4%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.2 Billion USD | 32.52% |
| 2022 | -1.78 Billion USD | -24.39% |
| 2021 | -1.43 Billion USD | 13.21% |
| 2020 | -1.65 Billion USD | -72.69% |
| 2019 | -959.89 Million USD | -36.01% |
| 2018 | -705.76 Million USD | -616.83% |
| 2017 | -98.45 Million USD | 15.89% |
| 2016 | -117.06 Million USD | -106.29% |
| 2015 | -56.74 Million USD | -260.13% |
| 2014 | -15.75 Million USD | -188.7% |
| 2013 | -5.45 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -107.16 Million USD | 59.0% |
| 2024 Q1 | -261.34 Million USD | 31.9% |
| 2023 Q4 | -383.79 Million USD | -186.48% |
| 2023 Q1 | -371.25 Million USD | 20.78% |
| 2023 Q3 | -133.96 Million USD | 57.97% |
| 2023 Q2 | -318.71 Million USD | 14.15% |
| 2023 FY | -1.2 Billion USD | 32.52% |
| 2022 Q4 | -468.62 Million USD | -6.9% |
| 2022 FY | -1.78 Billion USD | -24.39% |
| 2022 Q3 | -438.35 Million USD | 0.24% |
| 2022 Q2 | -439.39 Million USD | 0.88% |
| 2022 Q1 | -443.28 Million USD | 22.47% |
| 2021 Q1 | 70.16 Million USD | 114.47% |
| 2021 Q2 | -474.83 Million USD | -776.73% |
| 2021 Q3 | -462.32 Million USD | 2.64% |
| 2021 FY | -1.43 Billion USD | 13.21% |
| 2021 Q4 | -571.73 Million USD | -23.67% |
| 2020 FY | -1.65 Billion USD | -72.69% |
| 2020 Q2 | -358.87 Million USD | 3.98% |
| 2020 Q3 | -440.13 Million USD | -22.64% |
| 2020 Q4 | -484.91 Million USD | -10.17% |
| 2020 Q1 | -373.75 Million USD | 3.68% |
| 2019 Q1 | -173.75 Million USD | 38.12% |
| 2019 FY | -959.89 Million USD | -36.01% |
| 2019 Q2 | -85.83 Million USD | 50.6% |
| 2019 Q3 | -312.26 Million USD | -263.81% |
| 2019 Q4 | -388.03 Million USD | -24.26% |
| 2018 FY | -705.76 Million USD | -616.83% |
| 2018 Q4 | -280.8 Million USD | -85.84% |
| 2018 Q3 | -151.1 Million USD | 7.33% |
| 2018 Q2 | -163.05 Million USD | -47.15% |
| 2018 Q1 | -110.8 Million USD | -6.75% |
| 2017 Q2 | -58.02 Million USD | -12.57% |
| 2017 Q1 | -51.54 Million USD | -38.29% |
| 2017 FY | -98.45 Million USD | 15.89% |
| 2017 Q4 | -103.79 Million USD | -190.33% |
| 2017 Q3 | 114.9 Million USD | 298.04% |
| 2016 FY | -117.06 Million USD | -106.29% |
| 2016 Q2 | -24.62 Million USD | -21.12% |
| 2016 Q4 | -37.27 Million USD | -7.01% |
| 2016 Q3 | -34.82 Million USD | -41.42% |
| 2016 Q1 | -20.33 Million USD | 22.91% |
| 2015 Q4 | -26.37 Million USD | -88.51% |
| 2015 FY | -56.74 Million USD | -260.13% |
| 2015 Q1 | -9.81 Million USD | -52.05% |
| 2015 Q2 | -6.56 Million USD | 33.09% |
| 2015 Q3 | -13.99 Million USD | -113.13% |
| 2014 Q2 | -1.79 Million USD | 0.0% |
| 2014 Q3 | -5.72 Million USD | -219.2% |
| 2014 Q1 | -1.79 Million USD | 0.0% |
| 2014 FY | -15.75 Million USD | -188.7% |
| 2014 Q4 | -6.45 Million USD | -12.81% |
| 2013 FY | -5.45 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 1882.163% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 234.499% |